NASDAQ:ACOR

Acorda Therapeutics Stock Forecast, Price & News

$4.46
+0.10 (+2.29 %)
(As of 09/23/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.37
$4.49
50-Day Range
$3.36
$4.73
52-Week Range
$2.76
$9.84
Volume41,546 shs
Average Volume798,501 shs
Market Capitalization$49.61 million
P/E Ratio1.04
Dividend YieldN/A
Beta0.67
30 days | 90 days | 365 days | Advanced Chart
Receive ACOR News and Ratings via Email

Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Acorda Therapeutics logo

About Acorda Therapeutics

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine) and Selincro (nalmefene). The firm's also offers Research and Development Programs like ARCUS for acute migraine, Cimaglermin alfa and rHIgM22. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.03 out of 5 stars

Medical Sector

548th out of 1,351 stocks

Biological Products, Except Diagnostic Industry

85th out of 193 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Acorda Therapeutics (NASDAQ:ACOR) Frequently Asked Questions

Is Acorda Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acorda Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Acorda Therapeutics stock.
View analyst ratings for Acorda Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Acorda Therapeutics?

Wall Street analysts have given Acorda Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Acorda Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Acorda Therapeutics?

Acorda Therapeutics saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 939,400 shares, a decline of 33.4% from the August 15th total of 1,410,000 shares. Based on an average daily volume of 1,110,000 shares, the days-to-cover ratio is currently 0.8 days.
View Acorda Therapeutics' Short Interest
.

When is Acorda Therapeutics' next earnings date?

Acorda Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 2nd 2021.
View our earnings forecast for Acorda Therapeutics
.

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics, Inc. (NASDAQ:ACOR) issued its quarterly earnings data on Wednesday, August, 4th. The biopharmaceutical company reported ($1.87) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($2.09) by $0.22. The biopharmaceutical company earned $31.79 million during the quarter, compared to analysts' expectations of $29.94 million. Acorda Therapeutics had a net margin of 22.44% and a trailing twelve-month return on equity of 14.38%.
View Acorda Therapeutics' earnings history
.

How has Acorda Therapeutics' stock price been impacted by COVID-19?

Acorda Therapeutics' stock was trading at $6.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ACOR shares have decreased by 26.4% and is now trading at $4.46.
View which stocks have been most impacted by COVID-19
.

When did Acorda Therapeutics' stock split? How did Acorda Therapeutics' stock split work?

Shares of Acorda Therapeutics reverse split on the morning of Monday, January 4th 2021. The 1-6 reverse split was announced on Thursday, December 31st 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 31st 2020. An investor that had 100 shares of Acorda Therapeutics stock prior to the reverse split would have 17 shares after the split.

What price target have analysts set for ACOR?

1 Wall Street analysts have issued 1 year price targets for Acorda Therapeutics' shares. Their forecasts range from $10.00 to $35.00. On average, they anticipate Acorda Therapeutics' share price to reach $22.50 in the next twelve months. This suggests a possible upside of 404.5% from the stock's current price.
View analysts' price targets for Acorda Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Acorda Therapeutics' key executives?

Acorda Therapeutics' management team includes the following people:
  • Ronald Cohen, President, Chief Executive Officer & Director
  • Robert Morales, Principal Financial & Accounting Officer
  • Andrew R. Blight, Chief Scientific Officer Emeritus
  • Burkhard Blank, Chief Medical Officer, Head-R&D
  • Lauren M. Sabella, Chief Commercial Officer

What is Ron Cohen's approval rating as Acorda Therapeutics' CEO?

39 employees have rated Acorda Therapeutics CEO Ron Cohen on Glassdoor.com. Ron Cohen has an approval rating of 55% among Acorda Therapeutics' employees. This puts Ron Cohen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Acorda Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), InterDigital (IDCC), Nektar Therapeutics (NKTR), Rigel Pharmaceuticals (RIGL), Novan (NOVN), SCYNEXIS (SCYX), Acasti Pharma (ACST) and Applied Materials (AMAT).

What is Acorda Therapeutics' stock symbol?

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

Who are Acorda Therapeutics' major shareholders?

Acorda Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (7.53%), Vanguard Group Inc. (3.59%), Susquehanna International Group LLP (0.00%), Bridgeway Capital Management LLC (1.07%), Dimensional Fund Advisors LP (0.82%) and Geode Capital Management LLC (0.78%). Company insiders that own Acorda Therapeutics stock include Jane Wasman and Ron Cohen.
View institutional ownership trends for Acorda Therapeutics
.

Which major investors are selling Acorda Therapeutics stock?

ACOR stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Susquehanna International Group LLP, Bank of Montreal Can, and Simplex Trading LLC.
View insider buying and selling activity for Acorda Therapeutics
or view top insider-selling stocks.

Which major investors are buying Acorda Therapeutics stock?

ACOR stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Squarepoint Ops LLC, State Street Corp, Bridgeway Capital Management LLC, United Asset Strategies Inc., Dimensional Fund Advisors LP, Morgan Stanley, and Morgan Stanley.
View insider buying and selling activity for Acorda Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Acorda Therapeutics?

Shares of ACOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acorda Therapeutics' stock price today?

One share of ACOR stock can currently be purchased for approximately $4.46.

How much money does Acorda Therapeutics make?

Acorda Therapeutics has a market capitalization of $49.61 million and generates $152.97 million in revenue each year. The biopharmaceutical company earns $-99,590,000.00 in net income (profit) each year or ($12.32) on an earnings per share basis.

How many employees does Acorda Therapeutics have?

Acorda Therapeutics employs 344 workers across the globe.

When was Acorda Therapeutics founded?

Acorda Therapeutics was founded in 1995.

What is Acorda Therapeutics' official website?

The official website for Acorda Therapeutics is www.acorda.com.

Where are Acorda Therapeutics' headquarters?

Acorda Therapeutics is headquartered at 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502.

How can I contact Acorda Therapeutics?

Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at (914) 347-4300.


This page was last updated on 9/24/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.